BioSig Technologies Inc. Completes Strategic Merger with Streamex
In a significant development within the financial and digital asset sectors, BioSig Technologies Inc., a medical technology company known for its advancements in cardiac catheter ablation procedures, has completed a strategic merger with Streamex, a digital asset infrastructure company. This merger marks BioSig’s transition from the $16 billion cardiac market to the burgeoning digital asset infrastructure space.
Merger Details and Strategic Shift
The merger, finalized earlier in 2025, positions Streamex as one of the pioneering companies to offer gold-backed digital assets by a publicly listed entity. The newly launched platform by Streamex enables the issuance, trading, and custody of tokenized gold under full U.S. regulatory oversight. Each token represents fractional ownership of physical gold stored in off-chain vaults, providing users with borderless, auditable, and programmable access to monetary-grade bullion.
Market Impact and Growth
The tokenized gold market has seen significant growth, reaching over $1 billion in 2025, driven by increasing demand for stable assets. Streamex’s platform, backed by $1.1 billion, is a testament to the growing interest in digital asset infrastructure and the potential for innovation in the financial sector.
BioSig’s Transition
Previously, BioSig Technologies was a key player in the health care equipment and supplies industry, focusing on signal processing solutions for cardiac catheter ablations. The merger with Streamex signifies a complete shift in focus from cardiovascular health solutions to digital finance, aligning with the broader trend of technology companies diversifying into digital assets.
Investor Alert and Shareholder Investigation
In related news, BioSig Technologies Inc. has been the subject of investor alerts and shareholder investigations. The Former Attorney General of Louisiana, Kahn Swick, issued an investor alert concerning BioSig, highlighting the need for caution among investors. Additionally, Halper Sadeh LLC is investigating BioSig, along with other companies such as SCS, HLVX, and TTNP, on behalf of shareholders, indicating ongoing scrutiny in the financial activities surrounding BioSig.
Financial Overview
As of August 5, 2025, BioSig Technologies Inc. had a close price of $3.81, with a 52-week high of $14.11 and a low of $0.23. The company’s market capitalization stands at approximately $646.17 million, with a price-to-earnings ratio of -6.581, reflecting its current financial standing post-merger.
This strategic merger and the subsequent shift in focus highlight the dynamic nature of the tech and financial sectors, as companies like BioSig Technologies Inc. adapt to new opportunities in digital finance and asset tokenization.